MX2023009620A - Metodos terapeuticos. - Google Patents
Metodos terapeuticos.Info
- Publication number
- MX2023009620A MX2023009620A MX2023009620A MX2023009620A MX2023009620A MX 2023009620 A MX2023009620 A MX 2023009620A MX 2023009620 A MX2023009620 A MX 2023009620A MX 2023009620 A MX2023009620 A MX 2023009620A MX 2023009620 A MX2023009620 A MX 2023009620A
- Authority
- MX
- Mexico
- Prior art keywords
- therapeutic methods
- present disclosure
- inclusive
- administering
- dose
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163150301P | 2021-02-17 | 2021-02-17 | |
| PCT/US2022/016571 WO2022177968A1 (en) | 2021-02-17 | 2022-02-16 | Therapeutic methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023009620A true MX2023009620A (es) | 2023-11-01 |
Family
ID=82931154
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023009620A MX2023009620A (es) | 2021-02-17 | 2022-02-16 | Metodos terapeuticos. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250268902A1 (https=) |
| EP (1) | EP4294402A4 (https=) |
| JP (1) | JP2024507294A (https=) |
| KR (1) | KR20230157354A (https=) |
| CN (1) | CN117098538A (https=) |
| AU (1) | AU2022224562A1 (https=) |
| BR (1) | BR112023016459A2 (https=) |
| CA (1) | CA3211215A1 (https=) |
| MX (1) | MX2023009620A (https=) |
| WO (1) | WO2022177968A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026019771A1 (en) * | 2024-07-15 | 2026-01-22 | Celecor Therapeutics, Inc. | Zalunfiban for use in the treatment of thrombotic disorder in patients with renal impairment |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2804610B1 (en) * | 2012-01-16 | 2018-10-31 | The Rockefeller University | Organic compounds |
| US11684622B2 (en) * | 2018-06-19 | 2023-06-27 | Celecor Therapeutics, Inc. | Deuterated RUC-4 |
-
2022
- 2022-02-16 MX MX2023009620A patent/MX2023009620A/es unknown
- 2022-02-16 CA CA3211215A patent/CA3211215A1/en active Pending
- 2022-02-16 WO PCT/US2022/016571 patent/WO2022177968A1/en not_active Ceased
- 2022-02-16 US US18/277,364 patent/US20250268902A1/en active Pending
- 2022-02-16 CN CN202280025886.8A patent/CN117098538A/zh active Pending
- 2022-02-16 AU AU2022224562A patent/AU2022224562A1/en active Pending
- 2022-02-16 BR BR112023016459A patent/BR112023016459A2/pt unknown
- 2022-02-16 EP EP22756821.9A patent/EP4294402A4/en active Pending
- 2022-02-16 KR KR1020237031649A patent/KR20230157354A/ko active Pending
- 2022-02-16 JP JP2023574302A patent/JP2024507294A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022177968A1 (en) | 2022-08-25 |
| EP4294402A4 (en) | 2025-01-15 |
| WO2022177968A9 (en) | 2022-10-20 |
| EP4294402A1 (en) | 2023-12-27 |
| JP2024507294A (ja) | 2024-02-16 |
| CA3211215A1 (en) | 2022-08-25 |
| CN117098538A (zh) | 2023-11-21 |
| BR112023016459A2 (pt) | 2023-10-10 |
| KR20230157354A (ko) | 2023-11-16 |
| AU2022224562A1 (en) | 2023-08-31 |
| WO2022177968A8 (en) | 2022-11-17 |
| US20250268902A1 (en) | 2025-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20210563A (es) | Compuestos y métodos para el tratamiento de covid-19 | |
| MX2023000798A (es) | Peptidos funcionalizados como agentes antivirales. | |
| CR20230310A (es) | Inhibidores de prmt5 | |
| MX2023009222A (es) | Inhibidores tricíclicos-amido-bicíclicos de prmt5. | |
| MX2025001995A (es) | Compuesto heterociclico, procedimiento para prepararlo y uso farmaceutico del mismo | |
| PH12023550160A1 (en) | Combinations for the Treatment of Cancer | |
| MX2021005651A (es) | Combinacion farmaceutica para el tratamiento contra el cancer. | |
| MX2025005792A (es) | Combinaciones farmaceuticas y usos de las mismas | |
| WO2020033838A3 (en) | Treatment of egfr-mutant cancer | |
| MX2020010300A (es) | Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas. | |
| BR112013021566A2 (pt) | composto de fórmula, ou um aduto ou sal farmaceuticamente aceitável do mesmo e método de prevenção e/ou tratamento de um indivíduo que compreende a administração ao dito indivíduo uma quantidade terapeuticamente eficaz de um composto de fórmula | |
| PH12020551117A1 (en) | Compositions for preventing or treating uveitis | |
| MX2022009967A (es) | Compuestos para el tratamiento de la infeccion por coronavirus. | |
| PH12019500618A1 (en) | Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease | |
| MX2023011203A (es) | Derivado de cumarina para terapia o profilaxis de un trastorno proliferativo celular. | |
| ZA202000028B (en) | Use of vibegron to treat overactive bladder | |
| MX2023013225A (es) | Inhibidores de la cinasa 4 similar a polo. | |
| PH12023550780A1 (en) | Line-1 inhibitors to treat disease | |
| MX2022003845A (es) | Tratamientos cognitivos medicinales. | |
| TW200639159A (en) | Treatment of pain | |
| MX2020007817A (es) | Prevención y tratamiento del trastorno del sueño. | |
| MX2022011242A (es) | Inmunomodulación de o-het/aril azálidos. | |
| MX2022012001A (es) | Tratamiento preventivo de la migra?a. | |
| MX2023009620A (es) | Metodos terapeuticos. | |
| MX2023014898A (es) | Terapia combinada anti-vhc ventajosa. |